Royal London Asset Management Ltd. Lowers Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Royal London Asset Management Ltd. lowered its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 632,461 shares of the medical equipment provider's stock after selling 2,618 shares during the period. Royal London Asset Management Ltd.'s holdings in Boston Scientific were worth $56,491,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BSX. Generali Investments Management Co LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $2,414,000. Harvest Fund Management Co. Ltd raised its holdings in Boston Scientific by 94.3% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 14,126 shares of the medical equipment provider's stock valued at $1,262,000 after acquiring an additional 6,854 shares in the last quarter. Brooklyn FI LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth approximately $642,000. Xponance Inc. grew its holdings in shares of Boston Scientific by 5.1% during the 4th quarter. Xponance Inc. now owns 219,139 shares of the medical equipment provider's stock worth $19,573,000 after purchasing an additional 10,681 shares in the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Boston Scientific by 91.8% during the fourth quarter. Intech Investment Management LLC now owns 378,607 shares of the medical equipment provider's stock valued at $33,817,000 after purchasing an additional 181,220 shares during the period. Institutional investors own 89.07% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. UBS Group raised their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Citigroup upped their price objective on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Barclays raised their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Stifel Nicolaus upped their price target on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Finally, StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and an average price target of $108.91.

Insider Buying and Selling at Boston Scientific

In related news, CFO Daniel J. Brennan sold 67,333 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares of the company's stock, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 137,302 shares of company stock valued at $14,319,269. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Up 0.4 %

Shares of NYSE BSX traded up $0.42 during trading on Tuesday, reaching $103.09. The company had a trading volume of 9,345,997 shares, compared to its average volume of 5,771,894. The stock has a market cap of $152.48 billion, a P/E ratio of 82.47, a PEG ratio of 2.79 and a beta of 0.77. The company's fifty day moving average price is $101.84 and its 200-day moving average price is $92.65. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.